SAN DIEGO, June 15, 2023 /PRNewswire/ -- Diurnal Ltd., a Neurocrine Biosciences company (Nasdaq: NBIX), today announced that it will present new post hoc analyses of Phase 3 extension study data for modified-release hydrocortisone (approved as EFMODY® in United Kingdom and European Union), which is being investigated as a treatment for adults with congenital adrenal hyperplasia (CAH), at ENDO 2023 June 15–18 in Chicago. Diurnal Ltd. developed this modified-release formulation of hydrocortisone, which has been specifically designed to replicate the natural circadian release of cortisol.
Shares in Diurnal Group PLC (AIM:DNL) shot up 131% in early trade after its board accepted a knock-out offer from an acquisitive Californian biotech.
FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody® as treatment for congenital adrenal hyperplasia (CAH) in Switzerland. Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Efmody® in Switzerland.
Diurnal has announced that the first patient has been dosed in its phase 2 European clinical trial of modified-release hydrocortisone.
Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announced that it has signed a distribution agreement with ExCEEd Orphan, a company providing full business solutions for the treatment of rare diseases, for the distribution and marketing of Alkindi (hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsules) in Central and Eastern European (CEE) countries.
Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announced the commercial launch of Efmody (hydrocortisone modified-release hard capsules) in the United Kingdom as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH).
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the commercial launch of Efmody® (hydrocortisone modified-release hard capsules) in the United Kingdom as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). The launch of Efmody® follows its approval by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain (England, Wales and Scotland) in July 2021.
Congenital adrenal hyperplasia (CAH) is a rare condition caused by deficiency of adrenal enzymes